Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue (2022 - 2025)

Historic Non-Current Deffered Revenue for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $349.0 million.

  • Phathom Pharmaceuticals' Non-Current Deffered Revenue rose 824.94% to $349.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $349.0 million, marking a year-over-year increase of 824.94%. This contributed to the annual value of $333.3 million for FY2024, which is 1115.52% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Non-Current Deffered Revenue is $349.0 million, which was up 824.94% from $347.0 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $349.0 million for Q3 2025, and its period low was $109.5 million during Q4 2022.
  • In the last 4 years, Phathom Pharmaceuticals' Non-Current Deffered Revenue had a median value of $321.2 million in 2024 and averaged $270.2 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 17374.21% in 2023, then soared by 803.67% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Non-Current Deffered Revenue stood at $109.5 million in 2022, then surged by 173.74% to $299.8 million in 2023, then grew by 11.16% to $333.3 million in 2024, then increased by 4.72% to $349.0 million in 2025.
  • Its Non-Current Deffered Revenue stands at $349.0 million for Q3 2025, versus $347.0 million for Q2 2025 and $343.8 million for Q1 2025.